Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).
https://www.pharmalive.com/wp-content/uploads/2022/04/rick-winningham-theravance.jpg7691024BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-04-05 10:18:072022-04-05 11:21:08Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results